Duke University Health System has integrated Barostim into its comprehensive heart failure program. For patients with heart failure with reduced ejection fraction (HFrEF), Barostim is a device therapy that works with drug therapies to target the neurohormonal pathways responsible for heart failure progression and symptoms. Listen in as an advanced heart failure specialist discusses patient selection and post-implant management, the implant procedure, patient care pathways, and how Duke has incorporated Barostim into their system. 

Despite the use of effective drug and device therapies, many patients with HFrEF continue to experience worsening symptoms and disease progression. Barostim is a novel device therapy that works with drug therapies to target the neurohormonal pathways responsible for heart failure progression and symptoms. Patients feel better and their quality of life improves.